

The Editor,
World Journal of Gastroenterology

Re: Novel drug delivery systems for Inflammatory Bowel Disease (IBD)

Dear Sir/Madam

Attached, please find the revised manuscript based on the reviewers' comments.

We hope that your readership will enjoy reading it and will benefit from it. We like to take this opportunity to thank the reviewers and editorial staff for their time and patience. Please let us know with any questions.

Regards

Salim Surani, MD

Reviewers Comments

Title. Does the title reflect the main subject/hypothesis of the manuscript? YES 2 Abstract. Does the abstract summarize and reflect the work described in the manuscript? YES 3 Key words. Do the key words reflect the focus of the manuscript? YES 4 Background. Does the manuscript adequately describe the background, present status and significance of the study? YES 5 Methods. Does the manuscript describe methods (e.g., experiments, data analysis, surveys, and clinical trials, etc.) in adequate detail? YES 6 Results. Are the research objectives achieved by the experiments used in this study? What are the contributions that the study has made for research progress in this field? YES This review gives us a comprehensive description of the Enteric-coated microneedle pills, various nano-drug delivery techniques, prodrug systems, lipid-based vesicular systems, hybrid drug delivery systems, and biologic drug delivery systems in the treatment of IBD. 7 Discussion. Does the manuscript interpret the findings adequately and appropriately, highlighting the key points concisely, clearly and logically? Are the findings and their applicability/relevance to the literature stated in a clear and definite manner? Is the discussion accurate and does it discuss the paper's scientific significance and/or relevance to clinical practice sufficiently? YES, YES, YES 8 Illustrations and tables. Are the figures, diagrams and tables sufficient, good quality and appropriately illustrative of the paper contents? Do figures require labeling with arrows, asterisks etc., better legends? YES 9 Biostatistics. Does the manuscript meet the requirements of biostatistics? YES 10 Units. Does the manuscript meet the requirements of use of SI units? YES 11 References. Does the manuscript cite appropriately the latest, important and authoritative references in the introduction and discussion sections? Does the author self-cite, omit, incorrectly cite and/or over-cite references? YES, NO 12 Quality of manuscript organization and presentation. Is the manuscript well, concisely and coherently organized and presented? Is the style, language and grammar accurate and appropriate? YES 13 Research methods and reporting. Authors should have prepared their manuscripts according to manuscript type and the appropriate categories, as follows: (1) CARE Checklist (2013) - Case report; (2) CONSORT 2010 Statement - Clinical Trials study, Prospective study, Randomized Controlled trial, Randomized Clinical trial; (3) PRISMA 2009 Checklist - Evidence-Based Medicine, Systematic review, Meta-Analysis; (4) STROBE Statement - Case Control study, Observational study, Retrospective Cohort study; and (5) The ARRIVE Guidelines - Basic study. Did the author prepare the manuscript according to the appropriate research methods and reporting? YES 14 Ethics statements. For all manuscripts involving human studies and/or animal experiments, author(s) must submit the related formal ethics documents that were reviewed and approved by their local ethical review committee. Did the manuscript meet the requirements of ethics? YES In this manuscript, the authors reviewed several novel drug delivery systems that have been introduced to overcome several IBD-therapeutic obstacles, such as the problems of systematic drug reactions and low specificity in delivering drugs to the IBD-inflamed sites. Enteric-coated microneedle pills, various nano-drug delivery techniques, prodrug systems, lipid-

based vesicular systems, hybrid drug delivery systems, and biologic drug delivery systems have been comprehensively described and the manuscript is well-written and suggested to publish in our journal.

Response: We appreciate the reviewers positive feedback

1. Inflammatory Bowel Disease (IBD) is a chronic illness characterized by relapsing inflammation of the intestines. However, problems of systematic drug reactions and low specificity in delivering drugs to the inflamed sites have emerged with these regular routes of delivery. In this review, the author specify that novel carrier systems can be considered for targeting inflamed sites in IBD and discuss the implications of choosing such routes. This review has certain novelty, which is helpful for peers / readers to broaden their thinking, help to carry out relevant research and explore new treatment methods of IBD, and has guiding significance for improving the prognosis of IBD. 2. The title, abstract and keywords are accurate and basically reflect the content of the paper. The language is fluent and there is few grammatical error. 3. Expectation: More research is needed to substantiate the efficacy of the novel carrier systems.

Response: We appreciate the reviewers' comments. The grammar issue has been addressed and conclusion had been modified to reflect the suggested changes

(1) Science editor:

In this review, the authors suggest that new carrier systems can be considered to target inflammatory sites in IBD and discuss the implications of choosing such a route. The manuscript is well written. But it is better to add a discussion and a diagram that summarizes the munscripht.

Language Quality: Grade B (Minor language polishing)

Scientific Quality: Grade B (Very good)

Response: We appreciate the editors comments. We have added the diagram and summarized the manuscript in conclusion

(2) Company editor-in-chief:

I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Gastroenterology, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before final acceptance, the author(s) must add a table/figure (medical imaging) to the manuscript. There are no restrictions on the figures (color, B/W).

Response: The figure has been added